Related references
Note: Only part of the references are listed.Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients
Niels Weinhold et al.
HAEMATOLOGICA (2021)
Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
JingSong He et al.
FRONTIERS IN ONCOLOGY (2021)
Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents
Smith Giri et al.
BLOOD ADVANCES (2020)
Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities
Nadine Abdallah et al.
BLOOD ADVANCES (2020)
The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides
Jiadai Xu et al.
LEUKEMIA & LYMPHOMA (2020)
Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China
Wen Gao et al.
CANCER MEDICINE (2020)
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
V. Shah et al.
LEUKEMIA (2018)
Time to plateau as a predictor of survival in newly diagnosed multiple myeloma
Patrick W. Mellors et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy
Ayaz Ali Samo et al.
GENES CHROMOSOMES & CANCER (2018)
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation
Gunjan L. Shah et al.
LEUKEMIA & LYMPHOMA (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation
Fabian Bock et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens
Noa Biran et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value
Gang An et al.
HAEMATOLOGICA (2014)
Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis
J. Lu et al.
BLOOD CANCER JOURNAL (2014)
Rapidity and Quality of Response to Steroid-Based Induction Therapy, Without the Addition of Novel Agents, Does Not Affect Post Transplant Outcomes in Multiple Myeloma
Anca Prica et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib
Jan Smetana et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Rapid Early Monoclonal Protein Reduction After Therapy With Bortezomib or Bortezomib and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Myeloma Is Associated With a Longer Time to Progression
Jatin Shah et al.
CANCER (2011)
Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma
Soo-Mee Bang et al.
CANCER GENETICS AND CYTOGENETICS (2006)
Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27(Kip1) and an aggressive clinical course in multiple myeloma
J Shaughnessy
HEMATOLOGY (2005)
Share Paper
